Press Releases

Sporos BioDiscovery to Present Preclinical Findings on SPR1, a Next-Generation TEAD Inhibitor, at the American Association for Cancer Research (AACR) Annual Meeting 2023

HOUSTON, Texas., March 15, 2023 — Sporos BioDiscovery, Inc. (a wholly owned affiliate of Sporos Bioventures, “Sporos” or the “Company”), a precision oncology company developing a diversified pipeline of small molecule therapeutic programs targeting cancer vulnerabilities in the tumor and tumor microenvironment, today announced that it will present a poster highlighting preclinical data from the …

Sporos BioDiscovery to Present Preclinical Findings on SPR1, a Next-Generation TEAD Inhibitor, at the American Association for Cancer Research (AACR) Annual Meeting 2023 Read More »

Sporos BioDiscovery to Present at the Oppenheimer 33rd Annual Healthcare Conference

HOUSTON, Texas., March 8, 2023 — Sporos BioDiscovery, Inc. (a wholly owned affiliate of Sporos Bioventures, “Sporos” or the “Company”), a precision oncology company developing a diversified pipeline of small molecule therapeutic programs targeting cancer vulnerabilities in the tumor and tumor microenvironment, today announced the company’s Executive in Residence, Stephen Rubino, Ph.D., will present a …

Sporos BioDiscovery to Present at the Oppenheimer 33rd Annual Healthcare Conference Read More »

Sporos BioDiscovery Presents Preclinical Data on Differentiated TEAD Inhibitor Program, SPR1, at the 34th EORTC-NCI-AACR Symposium

SPR1 Demonstrates Single Agent Anti-Tumor Activity in vivo, Achieving Regression in Established, Large Volume Tumors SPR1 Synergizes with MAPK Inhibitors and Upstream Activators of the MAPK Pathway HOUSTON, Texas., October 26, 2022 — Sporos BioDiscovery, Inc. (a wholly owned affiliate of Sporos Bioventures, “Sporos” or the “Company”), a precision oncology company developing a diversified pipeline …

Sporos BioDiscovery Presents Preclinical Data on Differentiated TEAD Inhibitor Program, SPR1, at the 34th EORTC-NCI-AACR Symposium Read More »

FDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular Carcinoma

Houston, TX – October 19, 2022 – Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced that its lead product, TTI-101, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory locally advanced, unresectable, or metastatic …

FDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular Carcinoma Read More »

Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Idiopathic Pulmonary Fibrosis

Houston, TX – May 26, 2022 – Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced that its lead product, TTI-101, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF). The …

Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Idiopathic Pulmonary Fibrosis Read More »

Tvardi Therapeutics

Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Hepatocellular Carcinoma

Houston, TX – April 21, 2022 – Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced that its lead product, TTI-101, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of hepatocellular carcinoma (HCC). The FDA …

Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Hepatocellular Carcinoma Read More »

Data Demonstrating Tvardi’s TTI-101 Overcomes Palbociclib Resistance in Metastatic Breast Cancer Models to be Presented at the 2022 Annual Meeting of the American Association for Cancer Research

Houston, TX – April 7, 2022 – Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced its collaborators will present preclinical data demonstrating TTI-101 overcomes palbociclib resistance in metastatic breast cancer murine models at the upcoming 2022 Annual Meeting of the American Association for Cancer …

Data Demonstrating Tvardi’s TTI-101 Overcomes Palbociclib Resistance in Metastatic Breast Cancer Models to be Presented at the 2022 Annual Meeting of the American Association for Cancer Research Read More »

Nirogy Therapeutics Appoints Simon Pedder, Ph.D., as Chief Executive Officer

Appointment Strengthens Leadership and Expertise to Drive Lead Oncology Program into Phase 1 Clinical Development Founding Chief Executive Officer Dr. Vincent Sandanayaka transitions to role of President and Chief Scientific Officer Boston, Jan. 12, 2022 — Nirogy Therapeutics (“Nirogy” or “the Company”), a privately-held biotechnology company developing novel small molecules to target cellular transporters, today …

Nirogy Therapeutics Appoints Simon Pedder, Ph.D., as Chief Executive Officer Read More »

Sporos Bioventures Announces Formation of Strategic Advisory Board

Dr. Doug Williams to Chair SAB Inaugural members include Drs. Keith Flaherty, Bing Yao, and Doug Hanahan to advise on company’s growing pipeline and discovery engine HOUSTON, Texas., January 11, 2022 — Sporos Bioventures, LLC, (“Sporos” or the “Company”) a private biotechnology company catalyzing the rapid development of potential breakthrough therapies that target novel disease …

Sporos Bioventures Announces Formation of Strategic Advisory Board Read More »

Sporos Bioventures Appoints Dr. Rachel Humphrey to Board of Directors

HOUSTON–(BUSINESS WIRE)– Sporos Bioventures, LLC (“Sporos” or the “Company”), a private biotechnology company catalyzing the rapid development of breakthrough therapies through a portfolio of companies that target novel disease mechanisms in oncology and immune-related diseases, today announced the appointment of Rachel Humphrey, M.D. to its Board of Directors. “We are thrilled to welcome Rachel to …

Sporos Bioventures Appoints Dr. Rachel Humphrey to Board of Directors Read More »

Scroll to Top